AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00329901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saline placebo
Description: 4.5 mg sodium chloride per 0.5 ml dose
Study NCT02289716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study NCT02289716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
Study NCT02289716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
Study NCT02890108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverages
Description: 350 cc (1 can) of sugar sweetened beverage
Study NCT02890108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages
Description: 350 cc (1 can) of artificially sweetened beverage
Study NCT01585519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Description: (Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily.
Study NCT04579887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations
Description: Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
Study NCT02083549 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
Study NCT04656899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders messages to improve adherence.
Description: If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose.
Study NCT02407652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: 10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
Study NCT02407652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Cognitive Load Training
Description: 10 low cognitive load sessions, 400 trials each
Study NCT00665314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor (AMD3100)
Description: 0.24mg/kg SC for 2 to 7 days.
Study NCT00665314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Can be any registered nonpegylated form of G-CSF
Description: 10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
Study NCT01215266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Day 3-21 2x2 800 mg(milligram) daily
Study NCT01215266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 3-21 2x2 800 mg(milligram) daily
Study NCT04322500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
Study NCT01931215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia with intrathecal morphine
Description: in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
Study NCT01931215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP-block with ropivacaine and clonidine
Study NCT04598191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done.
Study NCT04598191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (Normal saline)
Description: Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done.
Study NCT03772002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV screening
Description: HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
Study NCT02788279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
Description: Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Study NCT02788279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Study NCT02788279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Study NCT04674540 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT01529775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Prevail
Description: Osseotite implant with platform switching feature
Study NCT01529775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite Certain Tapered
Description: Osseotite implant with non-platform switching feature
Study NCT02024152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV high dose
Study NCT02024152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IV low dose
Study NCT01169779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT01169779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT02024152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 IM
Study NCT01169779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT01169779 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT02024152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Zyrtec
Study NCT03449784 — intervention group
Intervention type: OTHER
Intervention: Detection of patients with dyslipidemia
Description: Detection of patients with dyslipidemia
Study NCT00618098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octaplex (human prothrombin complex concentrate)
Description: INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
Study NCT00618098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
Study NCT00838864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftrioxone
Description: 500 mg iv q12h for 3 days
Study NCT00838864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftrioxone
Description: 500 mg q12h for 7 days
Study NCT01101308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (Totowa) (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
Study NCT01101308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reformulated OXY (Wilson) (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
Study NCT04837326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel Lance Blood Sampling in Facilitated Tucking Position
Study NCT04837326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel Lance Blood Sampling When the Infant is Embraced by the Mother
Study NCT04837326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel Lance Blood Sampling Using White Noise
Study NCT04220593 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS associated with Tcog
Description: 2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
Study NCT04220593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS associated with Tcog
Description: 2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
Study NCT01169779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
Study NCT01169779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
Study NCT01169779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
Study NCT01169779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
Study NCT02834910 — intervention group
Intervention type: OTHER
Intervention: collection of bacterial sample
Study NCT00348621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visual impairment intervention program
Description: enhanced access to eye care services
Study NCT01736904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wXELIRI regimen
Description: irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
Study NCT01736904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
Study NCT04122287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: levofloxacinn-tetracycline-containing quadruple regimens
Study NCT04122287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole
Description: tinidazole-tetracycline-containing quadruple regimens
Study NCT00603239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
Study NCT00603239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
Study NCT02508155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352 for IV infusion
Description: MEDI7352 for IV infusion
Study NCT02508155 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IV infusion
Description: IV Placebo infusion
Study NCT02508155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352 for Subcutaneous Injection
Description: MEDI7352 for subcutaneous injection
Study NCT02508155 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Subcutaneous Injection
Description: Subcutaneous Placebo Injection
Study NCT00734084 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Preservation Unicompartmental Knee
Description: Minimally invasive orthopaedic implant for single compartment knee arthritis
Study NCT03180814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
Study NCT03180814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration
Description: A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
Study NCT02111278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Manipulation
Description: The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
Study NCT02111278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Manipulation
Description: The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
Study NCT04322500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Study NCT02111278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
Study NCT04322500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
Study NCT03482427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Heart Score
Description: Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
Study NCT02073604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy volunteers
Description: Morphological and functional brain MRI; transcranial magnetic stimulation
Study NCT02073604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Congenital mirror movements
Description: Morphological and functional brain MRI; transcranial magnetic stimulation
Study NCT01497652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rasagiline/Placebo
Description: Will receive placebo pills each day for the entire 14 weeks.
Study NCT01497652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: 0.5 mg for two weeks, then 1 mg for 12 weeks.
Study NCT03374280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed/cisplatin intercalating gefitinib
Study NCT03374280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed/cisplatin
Study NCT01970176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.